Telehealth addiction treatment now allowed under federal law
S. 3048 — TREATS Act · Filed by Lisa Murkowski (R-AK) · 22 cosponsors · Introduced Oct 23, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill amends the Controlled Substances Act to permit doctors to conduct telehealth evaluations (remote video or phone consultations) as part of the initial assessment for prescribing FDA-approved addiction medications in schedules III–V. Currently, federal law requires at least one in-person medical evaluation before any controlled-substance prescription for substance-use disorder; this bill adds a telehealth option alongside that requirement, expanding access to addiction treatment in underserved areas and reducing barriers to care.
Why we flagged it
The bill's operative mechanism is a straightforward expansion of treatment access by permitting telehealth as an alternative to in-person evaluation for addiction medications. It is a public-health measure, not a regulatory carve-out or industry giveaway.
What the text implies
- Telehealth expansion may increase prescribing volume for schedule III–V addiction medications if barriers to access were the primary constraint; outcomes depend on state-level telehealth licensing reciprocity and insurance coverage.
- The bill does not address reimbursement or insurance coverage for telehealth addiction evaluations, so access gains may be uneven across insured vs. uninsured populations.
The full analysis lists 3 implications of this text.
Who stands to gain
telehealth platforms and providers offering addiction-treatment services; pharmaceutical manufacturers of schedule III–V addiction medications (increased prescribing volume p; healthcare systems and clinics in underserved areas (expanded patient reach)